Skip to main content
TipRanks
Go Ultimate75% OFF

Daikin (DKI) Q1 2026 Earnings Report

19 Followers

DE:DKI Q1 2026 EPS Results

Actual EPS
EUR 1.58
Consensus EPS
EUR 1.66
Beat/Miss
Missed by -EUR 0.08
One Year Ago EPS
EUR 1.57

DE:DKI Q1 2026 Revenue Results

Actual Revenue
EUR 8.04B
Expected Revenue
EUR 7.60B
Beat/Miss
Beat by +EUR 436.60M
YoY Revenue Growth
+17.55%

Earnings Announcement Details

Quarter
Q1 2026
Date
08/04/2026
Time
Before Open
Conference Call
Tuesday, August 4, 2026
DE:DKI Upcoming Earnings

Daikin's next earnings date is estimated for February 9, 2027, based on past reporting schedules.

Q1 2026 Earnings Call Audio

DE:DKI Q1 2026 Earnings Call
0:00 / 0:00

Q1 2026 Earnings Slide Deck

Q1 2026 Earnings Call Summary

Q1 2026
Earnings Call Date:Aug 04, 2026|% Change Since:1.24%|
Earnings Call Sentiment|Neutral

The call conveyed a mixed picture: management reported strong profitability progress in Q1 — including a 10% operating margin, absorbed near-term tariff effects (JPY 7.5 billion) and regionally strong performances (DNA sales +13% local currency, DNA margin +2pp) — while acknowledging persistent demand weakness in key end markets (US housing, China real estate), significant declines in the chemicals business, inventory and tariff uncertainties, and Q1 sales slightly below plan. Management emphasized a clear shift to profit-oriented management, pricing discipline, and continued investment to drive recovery.

Company Guidance

Management reiterated guidance to “further exceed” its FY2026 operating profit plan of JPY435 billion, saying the May-estimated tariff hit of about JPY47 billion is now expected to be less than JPY47 billion and that Q1’s direct tariff impact of ≈JPY7.5 billion was fully absorbed by ~JPY5.0 billion of price increases and ~JPY2.5 billion of cost reductions; Q1 delivered a 10% operating margin (above plan). Key metrics cited: DNA sales were 113% of prior year (local currency) with DNA operating margin 11% (+2 pp) and DAA margin 9%; air‑conditioning real YoY sales by region were Europe 102%, China 93%, Americas 104%, Asia 90%; chemicals real YoY were Americas 115%, China 95%, Europe 99%; China residential multi‑split sales 99% YoY; heat‑pump heating sales 110% YoY. Management also noted R32 price rises of about 5% in April and 5% in May (selling‑price/product‑mix ~+7 pp to DNA), US industry shipments running ~84–85% in Q1, Win‑Back progress ~45% at end‑June, R410A distribution inventory expected to approach zero by end‑September, inventories slightly up in real terms but overall slightly below internal plan, and a commitment to further price increases, cost reductions, supply/production shifts and six group‑wide initiatives to meet targets.

  • Operating Profit Margin Improvement to 10% in Q1Company achieved an operating profit margin of 10% in Q1, exceeding its internal plan and described as record profit levels. Management expects to further exceed the annual operating profit plan (JPY 435 billion) if progress continues.
  • Tariff Impact Absorbed in Q1The direct negative impact of US tariff measures in Q1 was approximately JPY 7.5 billion on an operating profit basis and was fully absorbed through selling price increases (~JPY 5.0 billion) and cost reductions (~JPY 2.5 billion). Management now expects full-year tariff impact to be less than the previously announced JPY 47 billion, though uncertainty remains.
  • Solid Regional / DNA PerformanceAir conditioning sales in real terms (ex-FX) were: Europe 102% YoY, Americas 104% YoY, China 93% YoY, Asia 90% YoY. Daikin Comfort Technologies North America (DNA) sales were 113% of prior year on a local currency basis, with DNA operating margin at 11% (up 2 percentage points YoY).
  • Growth in Select Chemicals & Heat Pump SegmentsChemicals sales in the Americas expanded (real YoY 115%) and sales of coating materials for LAN/data-center cables grew. Heat pump hot-water heating sales in Europe were 110% of the prior year, indicating market share gains in a weak recovery.
  • Improved Profit Focus and Pricing ExecutionManagement shifted to profit-oriented budget management: implemented strategic selling price measures (e.g., R32 price increases ~5% in April and ~5% in May leading to ~7 percentage points effective selling-price contribution in DNA) and promoted higher sales mix of high value-added products and cost reductions. Q1 gross profit exceeded internal plan despite slightly lower sales.
  • CapEx, R&D and Investment Plans IntactCompany continues planned investments in production capacity, R&D and digital initiatives; no changes to annual capital expenditure, depreciation or R&D plans were announced.

DE:DKI Earnings History

DE:DKI earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 09, 20272026 (Q3)1.17-0.66――
Nov 05, 20262026 (Q2)1.691.871.5322.33% (+0.34)
Aug 04, 20262026 (Q1)1.661.581.570.78% (+0.01)
May 12, 20262025 (Q4)1.221.541.52.31% (+0.03)
Feb 04, 20262025 (Q3)1.110.660.67-1.76% (-0.01)
Nov 05, 20252025 (Q2)1.481.531.7-10.34% (-0.18)
Aug 05, 20252025 (Q1)1.361.571.2129.18% (+0.35)
May 08, 20252024 (Q4)1.311.501.2817.42% (+0.22)
Feb 05, 20252024 (Q3)1.170.670.79-14.19% (-0.11)
Nov 06, 20242024 (Q2)1.431.701.421.72% (+0.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed